Skip to main content

Table 1 Univariate analysis (log rank test)

From: Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study

Patient characteristics Total (%) n = 464 Deceased (% of the total) Median (IQR) survival (months) p value
Gender     0.56
 Male 353 (76) 292 (83) 14.2 (7.0-29.5)  
 Female 111 (24) 100 (90) 14.2 (9.3-28.9)  
Age (by quartile)     0.84
  < 54 years 112 (24) 96 (86) 13.7 (7.7-28.8)  
 54-60 years 112 (24) 95 (85) 13.5 (8.4-30.1)  
 60-67 years 117 (25) 96 (82) 15.6 (7.3-30.1)  
  ≥ 67 years 123 (27) 105 (85) 13.8 (6.9-27.9)  
Performance status     4.10−4
 0 183 (39) 149 (81) 16.8 (10.3-35.5)  
 1 261 (56) 224 (86) 12.2 (6.4-28.0)  
 2 20 (4) 19 (95) 6.0 (2.8-13.9)  
Charlson comorbidity index[[18]]     0.71
 0 378 (81) 321 (85) 13.6 (7.3-28.9)  
  ≥ 1 86 (19) 71 (83) 15.3 (7.3-29.5)  
Histology     <10−4
 Adenocarcinoma 279 (60) 247 (89) 13.7 (7.1-27.9)  
 Squamous cell carcinoma 112 (24) 79 (71) 20.2 (9.2-63.5)  
 Large cell carcinoma 73 (16) 66 (90) 10.5 (6.3-20.2)  
Cancer spread     <10−4
 Localised (II IIIA) 83 (18) 49 (59) 35.5 (18.5-not reached)  
 Advanced (IIIB) 97 (21) 75 (87) 20.2 (10.8-41.5)  
 Metastatic (IV) 284 (61) 268 (94) 10.5 (5.9-18.6)  
Platinum-based doublet     0.26
 Platinum-gemcitabine 179 (39) 150 (84) 15.8 (8.0-33.2)  
 Platinum-vinorelbine 77 (17) 64 (82) 15.2 (8.3-28.9)  
 Platinum-docetaxel 74 (16) 64 (86) 12.7 (7.3-21.8)  
 Platinum-paclitaxel 70 (15) 61 (87) 11.3 (4.3-26.9)  
 Platinum-pemetrexed 64 (14) 54 (84) 16.0 (8.1-29.9)  
Tumour response     <10−4
 Complete/partial response 146 (31) 108 (74) 20.8 (10.8-43.9)  
 Stable disease 245 (53) 213 (87) 14.6 (8.2-28.8)  
 Progressive disease 73 (16) 71 (97) 4.5 (2.7-8.3)  
  1. IQR: interquartile range.